Timothy Fendler, MD
Advanced Heart Failure and Transplant Cardiology · Lees Summit, MONPI 1639490030
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,000 of the $14,812 with a category attached, or 60.8%. 4 manufacturers reported payments, led by Impulse Dynamics (USA) Inc. at 44.0% of the total. 2025 is the largest year on record at $6,944, more than ten times the $464 reported in 2019.
Across 57 payments — averaging $259.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$7K
- Boston Scientific$5K
- Abbott$2K
- Cvrx, Inc.$703
Across 44 payments — averaging $5923.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$177K
- Impulse Dynamics (USA) Inc.$83K
What the payments were for
- Consulting fees$1,0007%
- Speaking & faculty fees$9,00061%
- Travel & lodging$1,62811%
- Food & beverage$3,16221%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 14 | $6,516 |
| Boston Scientific | 4 | $5,389 |
| Abbott | 35 | $2,205 |
| Cvrx, Inc. | 4 | $703 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,812 in reported general payments places this provider in the 65th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
See all advanced heart failure and transplant cardiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 202 | $209,385 |
| CamzyosMavacamten | 21 | $176,295 |
| EntrestoSacubitril/Valsartan | 104 | $112,372 |
| EliquisApixaban | 84 | $90,962 |
| OzempicSemaglutide | 37 | $50,829 |
| FarxigaDapagliflozin Propanediol | 51 | $43,945 |
| MounjaroTirzepatide | 24 | $31,859 |
| XareltoRivaroxaban | 18 | $17,955 |
| Tacrolimus | 91 | $14,568 |
| Repatha SureclickEvolocumab | 21 | $13,513 |
| Sirolimus | 21 | $6,877 |
| Eplerenone | 63 | $2,874 |
| Torsemide | 105 | $2,673 |
| Metoprolol Succinate | 135 | $1,319 |
| Atorvastatin Calcium | 108 | $1,294 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Lees Summit
- Andrew SauerLees Summit$411K
- Ahmad TurkLees Summit$502
- Gerard OghlakianSpringfield$365K
- Brett SperryKansas City$314K
- Shane LarueHannibal$41K
- Gregory EwaldSaint Louis$35K
- Sumanth PrabhuSaint Louis$35K
- Nancy SweitzerSaint Louis$32K
- Michael NassifKansas City$32K
- Justin HartupeeSaint Louis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.